Inicio › Cáncer de vejiga › Carolina del Norte
Ensayos clínicos de Cáncer de vejiga en Carolina del Norte
26 estudios sobre Cáncer de vejiga buscan participantes en Carolina del Norte.
Ciudades en Carolina del Norte
Texto oficial del estudio (inglés)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Margaret R Pardee Memorial Hospital, Hendersonville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03866382A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- WakeMed Raleigh Campus ( Site 0811), Raleigh
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07419295Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06770582The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
ReclutandoSe aceptan voluntarios sanos
Edades de 45 a 75 · Todos los sexos · Actualizado el 6 nov 2026 · NCT06995898A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Biorepository and Precision Pathology Center (BRPC), Durham
- Duke Cancer Institute, Durham
- Substrate Services Core Research Support (SSCRS), Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07206225Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- y 6 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05614739Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- Duke Cancer Center Cary, Cary
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT07097142Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- University of North Carolina, Chapel Hill
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 oct 2026 · NCT07225127Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Duke Cancer Center Cary, Cary
- Duke University Medical Center (location of scans), Durham
- Duke University Medical Center - Duke University Hospital (location of scans), Durham
- y 5 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT07421700A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Levine Cancer Institute, Charlotte
- Oncology Specialists of Charlotte, Charlotte
- Wake Forest Baptist Health, Winston-Salem
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 oct 2026 · NCT07218380DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
ReclutandoEstudio observacional
Edades de 18 a 130 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07124000Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT05267626A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Duke University Medical Center - Duke Cancer Center, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07217171ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT05059444Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- University of North Carolina, Chapel Hill
- Atrium Health/Levine Center, Charlotte
- Associated Urologist of North Carolina (Solaris), Raleigh
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06567743Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Chapel Hill
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT07129993LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- UNC Chapel Hill Hospital, Chapel Hill
- Duke Health - Duke Cancer Center, Durham
- Associated Urologists of North Carolina, Raleigh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 ago 2026 · NCT04752722A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
ReclutandoFase 2
Edades de 8 en adelante · Todos los sexos · Actualizado el 27 jul 2026 · NCT05503797A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
- UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill
- Carolinas Medical Center (biopsy only), Charlotte
- y 10 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT04879329PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 jul 2026 · NCT06896162Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 19 a 110 · Todos los sexos · Actualizado el 29 jun 2026 · NCT02012699Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy
- Duke University, Durham
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 may 2026 · NCT06986304Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 feb 2026 · NCT07030257A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT06778863SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.